Close Menu

The Scan

No New Concerns

Reuters reports that no serious safety concerns have been identified in the first month of SARS-CoV-2 vaccinations in the US.

In PLOS this week: actionable pharmacogenetic variants in Hong Kong population, role of defective viral genomes, and more.

Researchers have cloned the endangered black-footed ferret, the New York Times reports.

A High-Reaching ARIA

According to BBC News, the UK is to launch its new "high-risk" science agency.

Same Coyote, Again

DNA testing ties one coyote linked to three previous attacks to a new biting incident in the Bay Area, the San Francisco Chronicle reports.

In Science this week: cell-free DNA from urine explored to help diagnoses, more.

Lower Response

Two studies indicated that the SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna have lower neutralizing antibody responses to the B.1.351 viral lineage, according to the Washington Post.

The Chronicle of Higher Education reports that the number of international graduate students in the US has fallen during the COVID-19 pandemic.

CMS Nominee

According to Politico, President Joe Biden is to nominate Chiquita Brooks-LaSure to lead the Centers for Medicare and Medicaid Services.

In Nature this week: analysis of SARS-CoV-2 genomes uncovered substrains in the US.

The AP reports that a bill introduced to the US House of Representatives would provide $1.75 billion to sequence SARS-CoV-2 samples to spot viral changes.

The UK has given the go-ahead to a SARS-CoV-2 human challenge trial, Reuters reports.

CNN reports that a new study has found SNP chips do not reliably identify rare variants.

In Nucleic Acids Research this week: targeted splice sequencing study of myotonic dystrophy, structural variant genotyping tool, and more.

Bunch of Lineages

The New York Times writes that researchers have uncovered more than a half dozen SARS-CoV-2 lineages with a Q677P alteration.

Some Unused

The Wall Street Journal reports that a sizable portion of the 150 million rapid antigen tests the US bought have gone unused.

On a Pause

According to Stat News, Bluebird Bio has suspended its sickle cell gene therapy clinical trials after a patient developed leukemia.

In PNAS this week: single-cell whole-genome amplification approach for SNV detection, immune features linked to bone regeneration, and more.

Moving About

KTLA reports that a SARS-CoV-2 variant first identified in California is present across the US and abroad.

Reuters reports that France's sewage surveillance has found COVID-19 to be spreading quickly in three cities.

Japan is expected to approve the Pfizer-BioNTech SARS-CoV-2 vaccine Sunday, according to Bloomberg.

In Science this week: functional importance of NOVA1 in human evolution, and more.

Take a Load Off?

An initial analysis suggests the Pfizer-BioNTech vaccine could reduce viral load, the Guardian reports.

A new genome-wide association study in Nature Communications uncovers five dozen loci linked to frequency of afternoon naps.

Possible Early Cases

World Health Organization investigators have uncovered possible early cases of COVID-19 in central China, the Wall Street Journal reports.


New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.